Treosulfan FDA Approval Status
FDA Approved: No
Generic name: treosulfan
Company: Medexus Pharmaceuticals Inc.
Treatment for: Stem Cell Transplant Conditioning
Treosulfan is a bifunctional alkylating agent in development for use as part of a conditioning treatment for patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT).
Development timeline for treosulfan
| Date | Article |
|---|---|
| Jul 25, 2022 | Treosulfan NDA Resubmitted to FDA |
| Aug 3, 2021 | Complete Response Letter Received from FDA for Treosulfan |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
